Video

Additional Key Data Updates from ASH 2022 on Treatment of LBCL

Author(s):

Manali Kamdar, MDMatthew A. Lunning, DO, FACP

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Related Videos
Grzegorz S. Nowakowski, MD
Hua-Jay “Jeff” Cherng, MD, assistant professor, medicine, Lymphoma Program, Division of Hematology and Oncology, Columbia University Irving Medical Center
Joseph Maakaron, MD, assistant professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Marie Hu, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, the University of Minnesota Medical School
Jakub Svoboda, MD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Sattva S. Neelapu, MD
Sattva S. Neelapu, MD
Related Content
Nausheen Ahmed, MD, MBBS
July 24th 2024

Reduced Incidence of ICANS and CRS After 2 Weeks Post-CAR T Supports Shortened Monitoring Period in DLBCL

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Brentuximab Vedotin Triplet in R/R DLBCL Subgroups | Image Credit: © freshidea - stock.adobe.com
July 17th 2024

Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Francisco Hernandez-Ilizaliturri, MD
July 15th 2024

CAR T-Cell Therapy Selection in Follicular Lymphoma Requires Careful Consideration

Grzegorz S. Nowakowski, MD, of Mayo Clinic
July 12th 2024

Epcoritamab Shines in Third-Line Follicular Lymphoma With the Potential to Move into Earlier Lines